Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab
Sponsor: Shandong Cancer Hospital and Institute